A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR]

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

November 30, 2011

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

afatinib (BIBW 2992)

afatinib (BIBW 2992) po QD

Trial Locations (3)

1200.72.8201 Boehringer Ingelheim Investigational Site, Seoul

1200.72.8202 Boehringer Ingelheim Investigational Site, Seoul

1200.72.8203 Boehringer Ingelheim Investigational Site, Seoul